On March 20, 2026, Alzamend Neuro, Inc. received a notification from the Nasdaq Listing Qualifications staff indicating that the company's stockholders' equity, as reported in its recent 10-Q filing for the quarter ending January 31, 2026, fell short of the minimum requirement of $2.5 million mandated by Nasdaq Listing Rule 5550(b)(1). The reported stockholders' equity was approximately $2.2 million, which does not meet the threshold necessary for continued listing on the Nasdaq Capital Market. Despite this setback, the notification does not immediately affect the trading status of Alzamend's common stock, which will continue to be traded under the symbol 'ALZN'. The company has been granted a 45-day period to submit a plan to regain compliance, with a deadline set for May 4, 2026. If the plan is accepted, Nasdaq may allow an additional 180 days to demonstrate compliance. Alzamend is currently evaluating various strategies to address this issue and intends to submit its compliance plan within the stipulated timeframe. However, there is no guarantee that the plan will be accepted or that the company will be able to meet the compliance requirements within the given period. Failure to do so could result in a delisting notice from Nasdaq, although the company retains the right to appeal any such decision. This situation highlights the ongoing challenges faced by Alzamend in maintaining its listing status and the potential implications for its investors and stakeholders.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.